Related Experiment Video
Updated: May 31, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus
Sakiko Terui1,2, Taichi Minami2, Keita Nakamura3
1Department of Diabetes, Koyokai Kanto Hospital, Yokohama, Japan.
Journal of Lipid and Atherosclerosis
|May 29, 2026
Summary
Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, significantly lowers A1c and body weight in type 2 diabetes patients. It offers improved lipid profiles and blood pressure with manageable gastrointestinal side effects.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Tirzepatide is the first approved dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GLP-1) receptor agonist for diabetes mellitus.
- The SURPASS trials evaluated tirzepatide's efficacy and safety in type 2 diabetes patients.
Purpose of the Study:
- To review the pharmacodynamics, pharmacokinetics, and clinical trial findings of tirzepatide.
- To discuss tirzepatide's potential benefits in managing type 2 diabetes, atherosclerosis, and dyslipidemia.
Main Methods:
- Review of data from the phase III SURPASS clinical trials.
- Comparison of tirzepatide with placebo, basal insulin, semaglutide, and dulaglutide.
Main Results:
- Tirzepatide (5-15 mg) significantly reduced hemoglobin A1c (-1.87% to -2.58%) and body weight (-6.2 to -12.9 kg).
- Improvements were observed in lipid parameters and blood pressure without increased risk of serious hypoglycemia.
- Adverse events were primarily mild gastrointestinal symptoms, comparable to other GLP-1 receptor agonists.
Conclusions:
- Tirzepatide demonstrates significant efficacy in improving glycemic control and reducing weight in type 2 diabetes.
- Its favorable safety profile and potential cardiovascular benefits warrant further investigation for comprehensive diabetes management.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...